Literature DB >> 7091960

Toxic shock syndrome surveillance in the United States, 1980 to 1981.

A L Reingold, N T Hargrett, K N Shands, B B Dan, G P Schmid, B Y Strickland, C V Broome.   

Abstract

Between 1 January 1980 and 18 October 1981, investigators from the Centers for Disease Control collected information on 1407 cases of toxic shock syndrome using a nationwide passive surveillance system. Ninety-two percent of the reported cases were associated with menstruation. Information available on the type of menstrual device used shows that 99% of the cases occurred in tampon users. Menstrual cases occurred predominantly in whites (98%) under the age of 25 (65%). The case/fatality ratio for menstrual toxic shock syndrome was 3.1% for cases with onset in 1981. The distribution of reported cases by date of onset showed a gradual increase in the number reported before the summer of 1980, a sharp increase during the summer and early fall of 1980, a marked decrease in the late fall of 1980, and a subsequent gradual decrease. Factors affecting the incidence and reporting of toxic shock syndrome during these periods include changes in the number of tampon users, changes in the availability and usage patterns of tampons, changes in the prevalence of toxin-producing strains of Staphylococcus aureus, improved recognition of the syndrome, and publicity.

Entities:  

Mesh:

Year:  1982        PMID: 7091960     DOI: 10.7326/0003-4819-96-6-875

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  35 in total

1.  Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression.

Authors:  J M Musser; A R Hauser; M H Kim; P M Schlievert; K Nelson; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

2.  Cisplatin therapy-associated recurrent toxic shock syndrome.

Authors:  A C Berman; L R Boly
Journal:  West J Med       Date:  1991-10

3.  Determination by western blot (immunoblot) of seroconversions to toxic shock syndrome (TSS) toxin 1 and enterotoxin A, B, or C during infection with TSS- and non-TSS-associated Staphylococcus aureus.

Authors:  J L Whiting; P M Rosten; A W Chow
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

4.  Sequence of the toxic shock syndrome toxin gene (tstH) borne by strains of Staphylococcus aureus isolated from patients with Kawasaki syndrome.

Authors:  R L Deresiewicz; J Flaxenburg; K Leng; D L Kasper
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

5.  Toxic shock syndrome in Utah--1976 to 1983.

Authors:  J A Jacobson; C R Nichols; E M Kasworm
Journal:  West J Med       Date:  1985-09

Review 6.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

7.  Toxic shock syndrome.

Authors:  R Buchdahl; M Levin; B Wilkins; J Gould; P Jaffe; D J Matthew; M J Dillon
Journal:  Arch Dis Child       Date:  1985-06       Impact factor: 3.791

8.  Studies on staphylococci from toxic shock syndrome in France, 1981-1983.

Authors:  A K Melconian; J Fleurette; Y Brun
Journal:  J Hyg (Lond)       Date:  1985-02

9.  Toxic shock syndrome in the United States: surveillance update, 1979 1996.

Authors:  R A Hajjeh; A Reingold; A Weil; K Shutt; A Schuchat; B A Perkins
Journal:  Emerg Infect Dis       Date:  1999 Nov-Dec       Impact factor: 6.883

Review 10.  Models matter: the search for an effective Staphylococcus aureus vaccine.

Authors:  Wilmara Salgado-Pabón; Patrick M Schlievert
Journal:  Nat Rev Microbiol       Date:  2014-07-07       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.